Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benfo-oxythiamine add-on to Pluvicto in stable metastatic castration-resistant prostate cancer
2026-527059-25-00Phase 2Authorised
- Sponsor
- benfovir
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benfo-oxythiamine in metastatic castration-resistant prostate cancer (mCRPC), sponsored by benfovir. Primary endpoints: Incidence of dose-limiting toxicities, Safety and 1 more. Planned start Oct 2026; status: authorised.
02
Drugs
benfo-oxythiamine
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2026-527059-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527059-25-00.